- The BRAIN Foundation’s Synchrony Symposia is the first and only international symposium on translational research for Autism Spectrum Disorder (“ASD”)
- PaxMedica Chairman and CEO Howard Weisman says that participating at the symposium is pivotal in advancing and fostering autism research
- As a Gold Sponsor, PaxMedica will have purview to the symposium’s interdisciplinary discussions, insights, and research presentations, clinical roundtables, mentor-mentee sessions, and more
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship of The BRAIN Foundation’s esteemed Synchrony Symposia 2023. The BRAIN Foundation supports translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with ASD.
The Synchrony Symposia is the first and only international symposium on translational research for ASD – bringing together academia, biotech, pharmaceutical companies, venture partners, and more to catalyze scientific research that can improve health and the quality of life for people with autism and other neurodevelopmental disorders. The interdisciplinary forum brings together the brightest minds to collaborate and innovate, featuring CME-accredited presentations from leading scientists and clinicians.
“We are honored to support The BRAIN Foundation’s Synchrony Symposia. This symposium plays a pivotal role in advancing scientific knowledge and fostering collaboration among experts in the field of autism research,” said Howard Weisman, Chairman and CEO of PaxMedica (https://ibn.fm/iQCel). “PaxMedica is deeply committed to improving the lives of individuals with autism and their families, and we are excited to contribute to this vital initiative.”
Through its Gold Sponsorship, PaxMedica demonstrates its dedication to supporting research that can lead to advancements in understanding and treating ASD and other neurodevelopmental disorders. One of the company’s primary points of focus is developing and testing its lead program, PAX-101, an intravenous formulation of suramin for the treatment of ASD and advancing clinical understanding of using it for other disorders such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
The company’s robust pipeline of products, including PAX-101, may help eliminate, reduce, or modulate some of the more troublesome aspects of ASD. Both lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy known for over 100 years. Suramin was originally used for treating Human African Trypanosomiasis (“HAT”), or African Sleeping Sickness, which is currently in the company’s plan for raising funding for its ASD research and development efforts.
PaxMedica plans to use previously reported data for suramin to persuade the FDA to allow licensing to the company to use and subsequently license suramin to other pharmaceutical companies to treat rare occurrences of HAT in the United States. From those proceeds, the company will pursue its use of suramin for ASD research.
According to Fortune Business Insights, the global autism spectrum disorder therapeutics market was valued at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 at a CAGR of 7.9% from 2023 to 2030. By 2030, the market is expected to reach $3.42 billion (https://ibn.fm/0wQU9).
PaxMedica’s commitment to this cause aligns seamlessly with the Synchrony Symposium’s mission. As the only publicly traded U.S. company primarily focused on autism, PaxMedica is dedicated to developing groundbreaking therapies that address the unmet medical needs of individuals with ASD. The symposium offers a platform for attendees to engage in interdisciplinary discussions, gain insight, and participate in research presentations, clinical roundtables, mentor-mentee sessions, and more.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
MissionIR is powered by IBN